Search

everythinglearnresearchcommunity

for

Search:↓

The user is experiencing scalp irritation from a compounded treatment of finasteride, minoxidil, and tretinoin. They are considering switching to a non-alcohol, propylene glycol-free formula with a lower tretinoin percentage to reduce irritation.

The user experienced severe side effects from finasteride, including cognitive and sexual issues, despite its effectiveness for hair growth. They are considering switching to RU58841 and seek insights from others who have made a similar change.

RU58841 is discussed as a potential hair loss treatment, with comparisons to finasteride. There is interest in leaked trial data, but no official clinical validation or approval for RU58841.

User considers trying RU58841 for hair loss and asks for advice on its effectiveness and application. Responses vary, with some reporting positive results and others warning about potential risks or lack of change.

The conversation discusses the best carrier for RU58841, comparing Ethanol and PEG400. The user seeks advice on which carrier is more effective.

The conversation is about using Maxogen-X, a topical solution containing minoxidil, finasteride, tretinoin, and azelaic acid, for hair loss treatment. Users discuss their experiences, including initial shedding and the hope for thicker hair, while sharing progress updates.

The conversation discusses creating a customized minoxidil formulation with tretinoin, azelaic acid, and caffeine, but there are concerns about foam stabilization due to acidity. The user seeks advice on the best formulation for effective results.

User used Finasteride, Dutasteride, and Minoxidil for one year to treat hair loss. They discussed possibly trying RU58841 or pyrilutamide in the future.

Users discuss using pyrilutamide for hair loss, seeking alternatives to 5AR inhibitors. They mention using minoxidil, ketoconazole shampoo, and RU58841.

RU58841 powder from a lab supplier was tested at a free drug testing service. The discussion includes using Minoxidil and finasteride for hair loss treatment.

The drugs RU-58841, Pyrilutamide (KX-826), Apalutamide, Enzalutamide, and Darolutamide, which are nonsteroidal antiandrogens (NSAA), potentially impacting male fertility. Pyrilutamide, similar to Enzalutamide, may have reversible effects on fertility.

The user is experiencing breast tissue growth from taking dutasteride and minoxidil, and is considering reducing the dosage or stopping the medication. Suggestions include seeing an endocrinologist, using Raloxifene or Arimidex, and considering topical treatments or surgery if necessary.

The conversation discusses the effectiveness of RU58841 for hair loss compared to pyrilutamide, which failed to show significant hair regrowth in trials. Some users report personal side effects with RU58841 and question the criteria for success in hair loss treatments.

The user is not seeing hair regrowth after 12 weeks of using topical minoxidil and oral dutasteride, despite being on finasteride for 18 months, and is considering adding tretinoin. Another user suggests continuing the current treatment for 6-12 months before making changes.

A user is considering using compounded Minoxidil with Tretinoin from Medical Wellness Center to improve hair growth. They are also curious about the effects of higher Minoxidil doses and adding Tretinoin to their regimen.

RU58841 is used by some for hair loss when finasteride and minoxidil are ineffective. Users report mixed results, with some experiencing side effects like chest pain and mood changes.

The conversation is about the best vehicle for RU58841, comparing trichosol and Garnier/Vichy Stemoxydine, avoiding propylene glycol (PG) or ethanol due to previous scalp damage. The user is also seeking sources for these products in the EU.

An 18-year-old is seeking advice on microneedling while using RU58841 for hair loss. Recommendations include using a derma pen with 0.5mm needles every two weeks and avoiding RU application for 24 hours post-microneedling to prevent absorption into the bloodstream.

The user is considering splitting their 5 mg oral minoxidil dose into two 2.5 mg doses and is asking about starting tretinoin on the scalp, questioning if it should be used alone initially or with topical minoxidil. They also inquire if tretinoin significantly improved their hair loss treatment.

The routine involves using minoxidil, dermapen, and tretinoin for hair loss, with minoxidil applied daily and tretinoin used on alternate days. It is suggested to avoid using tretinoin and dermapen on the same day to prevent irritation.

User taking 1mg finasteride daily for 2 years, wants to block more scalp DHT. Seeks reference for additional topical DHT blockers like alfatradiol and fluridil.

Microneedling combined with tretinoin is discussed for its effectiveness in treating hair loss. Minoxidil, finasteride, and RU58841 are also mentioned as potential treatments.

A user started applying 25mg RU58841 daily for hair regrowth and is considering increasing the dosage. They are seeking advice on effective dosages from others who have experienced regrowth with RU58841.

The conversation is about the long-term safety trial results for pyrilutamide, which are expected soon. Treatments mentioned include Minoxidil, finasteride, and RU58841.

A participant using Veradermics VDPHL01, an extended-release oral minoxidil, experienced significant hair regrowth from Norwood 6 to Norwood 3V without side effects. They plan to use dutasteride after the treatment to maintain results.

Using a combination of finasteride, minoxidil, dermarolling, and RU58841 to treat hair loss. Participants discussed the time commitment required for treatment and the effectiveness of different dosages.

A user started using RU58841 for hair loss and experienced anxiety and physical discomfort. Other users suggested avoiding the treatment due to similar side effects and recommended alternative treatments like pyri.

A 16 year old's experience with using pyrilutamide to treat hair loss, and the potential side effects of adding tretinoin to minoxidil and finasteride treatments.

The conversation discusses organizing group buys and tracking progress for Kx-826 Pyrilutamide, a hair loss treatment. Participants express optimism about upcoming results and concerns about self-reporting bias.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.